Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Samsung Biologics (207940 KS)
Watchlist
292
Analysis
Health Care
•
South Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Wuxi Biologics
•
27 May 2017 01:58
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...
Kemp Dolliver, CFA
740 Views
Share
bullish
•
Wuxi Biologics
•
17 May 2017 05:40
WuXi Biologics: Updated Valuation Data
We have heard that WuXi Biologics' bankers are preparing to move forward with the offering though a PHIP has not been posted yet. The updated...
Kemp Dolliver, CFA
681 Views
Share
bullish
•
Samsung Electronics
•
14 May 2017 15:48
Samsung Restructuring Update - Newly Emerging Scenario & Regulatory Pushes
Samsung restructuring debate doesn't really seem to have ended. Among Korea's local investors, this just continues to be one of the topics that are...
Sanghyun Park
Follow
282 Views
Share
bearish
•
Celltrion Inc
•
22 Apr 2017 02:17
The Disconnect Is Growing
Celltrion Inc (068270 KS) 's Inflectra, a biosimilar to Johnson & Johnson (JNJ US) 's Remicade, had little impact on the critical U.S. market...
Kemp Dolliver, CFA
601 Views
Share
bearish
•
Samsung Biologics
•
11 Mar 2017 06:29
Reconsider the Samsung Bioepis Valuation
As noted in our Insight Pass on the Deal, Put on the Watchlist one of the underpinnings of the valuation of Samsung Biologics Co., Ltd (207940 KS)...
Kemp Dolliver, CFA
758 Views
Share
First
Previous
49
50
51
52
53
54
55
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.9
x